202 related articles for article (PubMed ID: 23636849)
1. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.
Nickerson ML; Im KM; Misner KJ; Tan W; Lou H; Gold B; Wells DW; Bravo HC; Fredrikson KM; Harkins TT; Milos P; Zbar B; Linehan WM; Yeager M; Andresson T; Dean M; Bova GS
Hum Mutat; 2013 Sep; 34(9):1231-41. PubMed ID: 23636849
[TBL] [Abstract][Full Text] [Related]
2. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
3. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
[TBL] [Abstract][Full Text] [Related]
5. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
6. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
8. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
[TBL] [Abstract][Full Text] [Related]
9. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
Cyrta J; Prandi D; Arora A; Hovelson DH; Sboner A; Rodriguez A; Fedrizzi T; Beltran H; Robinson DR; Gopalan A; True L; Nelson PS; Robinson BD; Mosquera JM; Tomlins SA; Shen R; Demichelis F; Rubin MA
J Pathol; 2022 Jul; 257(3):274-284. PubMed ID: 35220606
[TBL] [Abstract][Full Text] [Related]
10. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
[TBL] [Abstract][Full Text] [Related]
11. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
[TBL] [Abstract][Full Text] [Related]
12. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
[TBL] [Abstract][Full Text] [Related]
13. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
15. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
16. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
17. ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.
Vicentini C; Cantù C; Antonello D; Simbolo M; Mafficini A; Luchini C; Rusev B; Porcaro AB; Iacovelli R; Fassan M; Corbo V; Brunelli M; Artibani W; Scarpa A; Lawlor RT
Pathol Res Pract; 2018 Oct; 214(10):1675-1680. PubMed ID: 30190183
[TBL] [Abstract][Full Text] [Related]
18. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
19. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
20. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
